The global pharmaceutical industry experienced a 55% drop in company filings mentions of microbiome in Q1 2024 compared with the previous quarter, with the highest share accounted for by BioNTech with 50% year-on-year decrease, according to GlobalData’s analysis of over 34 pharmaceutical company filings. GlobalData’s Pharma: Filings Trends & Signals Q1 2024 report delves into earnings call transcripts and quarterly reports within the pharmaceuticals industry, extracting trends, signals, and comparative data to help businesses assess their performance, identify competitive intelligence, evaluate risks, and gain a comprehensive understanding of key industry events. Buy the report here.
Notably, microbiome was one of the most frequently referenced themes in Q1 2024, ranking highest in terms of mentions, ahead of governance and cybersecurity, according to GlobalData.
Of the top leading companies in the pharmaceutical industry, BioNTech had the greatest increase in references for microbiome in Q1 2024, compared with the previous quarter. GlobalData identified one microbiome-related sentences in the company's filings and a decrease of 50% in Q1 2024 compared with Q1 2023.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for microbiome in Q1 2024 was 60.
For further understanding of GlobalData's Pharma: Filings Trends & Signals Q1 2024, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.